Color duplex ultrasound-guided percutaneous transluminal angioplasty for hemodialysis-associated venous hypertension syndrome: A retrospective study of safety and efficacy.

Abstract

PurposeTo evaluate the efficacy and safety of ultrasound-guided percutaneous transluminal angioplasty for hemodialysis-associated venous hypertension syndrome caused by central venous stenosis or occlusion.Patients and methodsThe clinical data of 24 treatment instances with color duplex ultrasound-guided percutaneous transluminal angioplasty from January 2021 to January 2023 were retrospectively analyzed. The primary endpoint of the study was clinical success rate, while the secondary endpoints were 6- or 12-month vascular patency rates.ResultsOf the 24 treatment instances enrolled, 20 were primary onset and treated initially with percutaneous transluminal angioplasty under color duplex ultrasound guidance. Of these 20 patients, 17 were treated successfully (85%), while 3 procedures failed, requiring reoperation. Six patients showed recurrence within 1 year, of which four received repeated ultrasound-guided percutaneous transluminal angioplasty. Three of these procedures were successful (75.0%). Therefore, the total success rate was 83.3%. The patency rates were 76.5% at the 6-month follow-up and 64.7% at the 12-month follow-up. No patient developed complications such as dissection or perforation of the target vessel wall.ConclusionColor duplex ultrasound-guided percutaneous transluminal angioplasty is a feasible technique for hemodialysis-associated venous hypertension syndrome.